Artwork

Player FM - Internet Radio Done Right
Checked 4d ago
one 年前已添加!
内容由RealPharma提供。所有播客内容(包括剧集、图形和播客描述)均由 RealPharma 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!
icon Daily Deals

RealPharma: Conversations with Pharma Pathfinders

分享
 

Manage series 3535889
内容由RealPharma提供。所有播客内容(包括剧集、图形和播客描述)均由 RealPharma 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into biotechnology, pharmaceuticals, and healthcare.

RealPharma podcast aims to challenge your viewpoints, deepen your understanding of the pharma world beyond the headlines, and explore emerging trends in medical innovation.

  continue reading

31集单集

Artwork
icon分享
 
Manage series 3535889
内容由RealPharma提供。所有播客内容(包括剧集、图形和播客描述)均由 RealPharma 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into biotechnology, pharmaceuticals, and healthcare.

RealPharma podcast aims to challenge your viewpoints, deepen your understanding of the pharma world beyond the headlines, and explore emerging trends in medical innovation.

  continue reading

31集单集

所有剧集

×
 
🎙 RealPharma Podcast – Oncology Part 1: Understanding the Cancer Universe with Dr. Yaming Wang Cancer is one of the most complex and pressing challenges in modern medicine. But how much do we really understand about it? In this first episode of our two-part oncology deep dive, we sit down with Dr. Yaming Wang , founder of Alphabet Health, to break down the fundamentals of oncology and hematology . From the earliest discoveries in cancer research to today’s cutting-edge targeted therapies and immunotherapy , Dr. Wang shares his expertise on the science behind cancer, why it remains such a difficult disease to treat, and the role of communication in bridging the gap between innovation and patient care . 🔬 Topics we cover in this episode: ✔ The difference between solid tumors and blood cancers ✔ Why cancer is like its own universe in medicine ✔ How early detection and screening can make a difference ✔ The evolution of chemotherapy, targeted therapies, and immunotherapy ✔ Why science alone isn’t enough —effective communication is key Whether you're a biotech professional, healthcare communicator, or just curious about the latest in oncology, this episode is packed with insights you won’t want to miss. Resources: Dr. Yaming Wang on LinkedIn Alphabet Health LTD General Cancer Information & Education: 🔹 National Cancer Institute (NCI) – Comprehensive cancer research and education 👉 https://www.cancer.gov 🔹 American Cancer Society (ACS) – Trusted resource for cancer prevention, diagnosis, and treatment 👉 https://www.cancer.org 🔹 World Health Organization (WHO) – Cancer Fact Sheet – Global insights on cancer trends and impact 👉 https://www.who.int/news-room/fact-sheets/detail/cancer Oncology Research & Innovations: 🔹 American Society of Clinical Oncology (ASCO) – Latest breakthroughs in cancer treatment and clinical trials 👉 https://www.asco.org 🔹 National Comprehensive Cancer Network (NCCN) – Guidelines for cancer treatment and best practices 👉 https://www.nccn.org 🔹 ClinicalTrials.gov – Find ongoing cancer clinical trials worldwide 👉 https://clinicaltrials.gov Cancer Screening & Prevention: 🔹 CDC Cancer Prevention & Screening Guidelines – Know the recommended screening tests 👉 https://www.cdc.gov/cancer/dcpc/prevention/index.htm 🔹 Prevent Cancer Foundation – Focus on early detection and prevention strategies 👉 https://www.preventcancer.org Emerging Technologies & Future of Cancer Care: 🔹 Caris Life Sciences – Liquid Biopsy & Precision Oncology 👉 https://www.carislifesciences.com 🔹 National Cancer Institute – Immunotherapy Research 👉 https://www.cancer.gov/research/areas/treatment/immunotherapy 🔹 AI in Oncology: How Artificial Intelligence is Changing Cancer Detection (Article from Nature) 👉 https://www.nature.com/articles/d41586-020-00847-2 #RealPharmaPodcast #Oncology #CancerResearch #Biotech #Pharma #MedicalInnovation #Immunotherapy #Healthcare…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this episode of Real Pharma, hosts Na-Ri Oh and Ian Wendt engage with Joshua Kettner, co-founder of DreamBody Clinic, to explore the intricacies of stem cell therapy. They discuss the clinic's unique approach to regenerative medicine, the science behind mesenchymal stem cells, and the various applications and limitations of this therapy. The conversation also delves into the regulatory challenges faced in the US and how these impact the availability of such treatments. Kettner shares personal anecdotes and insights from his experience in the field, providing a comprehensive overview of the current landscape of stem cell therapy. In this conversation, Joshua Ketner discusses the complexities of stem cell therapy, including FDA regulations, economic challenges, and the importance of donor vetting. He highlights the risks and efficacy of treatments, the growing interest in longevity and anti-aging, and the vision behind his clinic's approach to regenerative medicine. The discussion emphasizes the need for better accessibility to these treatments for patients in need. Resources: Deam Body Clinic The Ultimate Guide to Stem Cell Therapy Stem Cell Research Learning Center Stem cells: What they are and what they do…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this riveting episode of RealPharma , hosts Na-Ri Oh and Ian Wendt sit down with the renowned ethnopharmacologist, Dennis McKenna , to explore the profound intersection of nature, science, and healing. From Dennis’s storied journey into the world of plant medicines to the evolving landscape of psychedelic therapies, this conversation is as thought-provoking as it is inspiring. Key Topics Discussed: 🌿 Dennis’s Journey: How an early fascination with psychedelics and traditional practices shaped his career in ethnopharmacology. 🌌 Modern Psychedelic Science: The exciting potential of compounds like Ibogaine and psilocybin for treating addiction, PTSD, and neurodegenerative disorders. 🌍 Ethical Dimensions: The importance of honoring indigenous knowledge and the call for reciprocity in drug development. 🔬 Challenges in Biopharma: Why current regulatory frameworks struggle with psychedelics and how innovation can bridge the gap. 🎤 McKenna Academy's Mission: Insights into biodiversity preservation, education, and the Academy’s role in advancing plant medicine research. Notable Moments: Dennis recounts the inspiration behind his 50-year journey in ethnopharmacology. A deep dive into the “set and setting” principle and its importance for both traditional and modern psychedelic practices. Discussion on how biopharma can balance commercialization with ethical responsibilities toward indigenous communities. Insights into the upcoming COCA Summit and its aim to shift perceptions and regulations around this misunderstood plant. Resources: Dennis McKenna on LinkedIn Dennis McKenna on Wikipedia McKenna Academy of Natural Philosophy Wisdom of the Leaf Coca Summit Dennis McKenna books Lykos path to MDMA approval…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
Year-End Wrap-Up with Kristiaan Rawlings In this episode of the Real Pharma Podcast, hosts Ian Wendt and Na-Ri Oh welcome back frequent guest Kristiaan Rawlings, a seasoned commercial pharmaceutical recruiter, for a year-end reflection on the pharmaceutical job market in 2024 and a look ahead to 2025. The discussion highlights key trends, challenges, and opportunities for candidates and employers alike. Key Highlights: Job Market Trends Executive Presence Hot Therapeutic Areas Advice for Candidates Employer Insights Looking to 2025 Resources: Kristiaan Rawlings on LinkedIn EPM Scientific Biospace: Top 12 Companies Hiring in Biopharma…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this episode of the Real Pharma Podcast, hosts Ian Wendt and Dr. Na-Ri Oh and guest Jason Scharf delve into the evolving landscape of TechBio, exploring its definition, the rise of bio innovation, and the challenges and opportunities it presents. They discuss the shift from traditional drug development methods to innovative approaches driven by technology, the importance of adapting business models in the pharmaceutical industry, and the need for a balanced regulatory framework that fosters innovation while ensuring safety. Jason shares insights on the future of drug development, the role of big pharma, and the necessity for a collaborative ecosystem to drive progress in healthcare. In this conversation, Jason Scharf discusses the evolving landscape of the TechBio sector, particularly in Austin, Texas. He highlights the intersection of science and policy, the growth of Austin as a tech bio hub, and the dynamics of the local ecosystem. Scharf emphasizes the importance of innovation, investment philosophy, and the future trends shaping the industry. He also shares personal insights on entrepreneurship and the significance of understanding one's skills and passions in driving change. Resources: Jason Scharf on LinkedIn Jason Scharf on X (Twitter) Austin Next Podcast…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this conversation, Roger Estafanos discusses the evolving field of radiopharmaceuticals, highlighting their transformative impact on cancer treatment and patient care. He explains the targeted nature of these therapies, the importance of personalized medicine, and the challenges faced in regulatory processes and patient safety. The discussion also covers the role of different radioisotopes, the complexities of supply chain management, and the need for improved access to these innovative treatments. The conversation delves into the complexities and advancements in the field of radiopharmaceuticals, focusing on logistics, future opportunities, investment landscapes, commercialization challenges, talent acquisition, and technological innovations. The speakers emphasize the importance of optimizing supply chains, the potential for expanding applications beyond oncology, and the role of AI in enhancing imaging processes. They also discuss the need for education among healthcare providers and patients, as well as the personal motivations driving their work in this evolving field. Resources: Roger Estafanos on LinkedIn **Society of Nuclear Medicine and Molecular Imaging (SNMMI)** Comprehensive resource on the use of radiopharmaceuticals in imaging and therapy: [ https://www.snmmi.org ] **Theragnostics Explained** An introduction to theragnostic approaches combining diagnostics and therapy: [ https://www.cancer.gov/about-cancer/treatment/types/theragnostic ] **U.S. Nuclear Regulatory Commission (NRC)** Guidelines for handling, licensing, and safe administration of radiopharmaceuticals: [ https://www.nrc.gov ] **FDA Guidance on Radiopharmaceuticals** Regulatory pathways and guidelines for the development of radiopharmaceuticals: [ https://www.fda.gov ] **Patient Advocacy in Radiopharmaceuticals** Information for patients and caregivers about radiopharmaceutical therapies: [ https://www.patientadvocate.org ] **Radiopharmaceutical Treatment Education** Tips and safety guidelines for patients undergoing radiopharmaceutical treatments: [ https://www.cancer.net ] **AI in Radiopharmaceutical Imaging** How AI is transforming diagnostic imaging and patient care: [ https://www.auntminnie.com ] **Global Radiopharmaceutical Market Reports** Market trends, forecasts, and analysis: [ https://www.globenewswire.com ]…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this conversation, Aaron Burnett, from Wheelhouse DMG, discusses the rapid evolution of digital marketing in the healthcare sector, emphasizing the importance of data strategy and compliance with regulations like HIPAA. He highlights the shift from third-party data reliance to first-party data utilization, which enhances marketing effectiveness and patient engagement. The discussion also covers the need for collaboration among marketing, compliance, and IT teams to develop effective data strategies and the role of customer data platforms in personalizing healthcare marketing efforts. In this conversation, the speakers delve into the complexities of data privacy, patient consent, and the ethical implications of using AI in healthcare. They discuss the transformative role of AI and machine learning in digital health, emphasizing the importance of first-party data and the need for compelling content. The conversation also touches on marketing strategies in a digital landscape, the evolution of media mix modeling, and the tools that enhance digital marketing efforts. Finally, the discussion concludes with an inspiring anecdote about unconventional thinking and the pursuit of personal fulfillment. Resources: Aaron Burnett on LinkedIn Wheelhouse DMG Digital Marketing 2024: The Complete Guide For Beginners…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this latest episode of RealPharma, we’re diving back into the fascinating world of AI in pharma, breaking down all the insights from our conversation with the brilliant Andree Bates! If you missed it or want to catch the highlights, this episode serves up a concise, punchy summary covering everything from predictive analytics to patient outcomes and beyond. But there's a twist. Our hosts, this time, bring a unique, fresh perspective to the conversation—you might notice something different about how they tackle the topic. Stick around until the end, and you’ll find out what makes this episode truly special. Curious? You won’t want to miss this one. Tune in, share your thoughts, and see if you can guess what’s up! Resources Andree Bates on LinkedIn Eularis AI in biopharma research: A time to focus and scale AI in Biopharma: Use Cases and Considerations Artificial intelligence and its expanding role across the biopharma landscape…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this episode, Dr. Na-Ri Oh and Ian Wendt sit down with Philip Vyt, a renowned expert in omnichannel strategy and founder of Shyft, a consultancy specializing in omnichannel approaches for biopharma. They delve into the key concepts behind omnichannel and its distinction from multichannel, emphasizing the centrality of healthcare professionals (HCPs) in engagement strategies. Philip breaks down the importance of personalized content delivery and the role of interconnected channels in creating a 360-degree view of HCP interactions. He also shares practical advice for biopharma companies—both large and small—on building effective omnichannel campaigns, starting with "minimal viable campaigns" to learn by doing. The conversation explores the challenges companies face, such as managing content supply chains and the integration of technology, while highlighting the significant investments needed in marketing technology (MarTech) for a truly effective omnichannel approach. Philip also discusses the differences between the U.S. and European markets in terms of data privacy and consent, as well as the evolving role of AI and automation in real-time engagement with HCPs. Throughout, Philip provides actionable insights on how companies can avoid common pitfalls, emphasizing a focus on execution and the importance of aligning marketing with commercial excellence. Listeners will gain a deeper understanding of what it takes to implement a successful omnichannel strategy and why it’s a journey that requires commitment, adaptation, and collaboration across teams. Resources: Philip Vyt on LinkedIn…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this episode, Dr. Na-Ri and Ian Wendt welcome back Kristiaan Rawlings, from EPM Scientific to discuss the latest trends in pharma and biotech hiring. They explore the key drivers of hiring, the impact of AI and advanced analytics, and the evolving expectations of candidates. Kristiaan emphasizes the importance of change agents in the industry and shares insights on the optimistic outlook for small biotechs and oncology. The conversation also touches on strategies for candidates to navigate career transitions and for companies to attract top talent in a competitive market. Resources: Kristiaan Rawlings on LinkedIn EPM Scientific BioSpace 2024 Employment Outlook BioSpace Complete Guide to the Biopharma Job Search BioSpace 2024 Job Search Toolkit…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this episode, Ian Wendt and Dr. Na-Ri Oh interview Michael C. Barnes, Chairman of the Center for US Policy, about the US opioid crisis. They discuss the evolution of US policy on opioids, the impact of the crisis on different communities, the role of legislation and harm reduction, the accountability of the pharmaceutical industry, barriers to accessing treatment, and the importance of advocacy in addressing stigma. The conversation explores various themes related to the substance use disorder crisis, including the lack of parity in insurance plans, the role of prescribers, the need for treatment and support, the potential for decriminalization, the economic impact of substance use disorders, and the US-centric nature of the problem. The guests discuss the importance of addressing substance use disorder as a health condition and providing therapeutic responses and harm reduction services. They also highlight the need for policies that focus on prevention, access to treatment, and economic opportunities for individuals in recovery. The conversation emphasizes the complexity of the issue and the need for comprehensive solutions. Resources: Michael Barnes on LinkedIn Center for US Policy NOPE Task Force Recovery Friendly Workplace Institute Pain News Network…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
Danny McBryan, an executive leader in the pharmaceutical industry, discusses the evolving role of medical affairs in healthcare. He highlights the importance of medical affairs in conveying the science of pharmaceutical companies and translating complex data into a meaningful narrative for healthcare providers, payers, patients, and policymakers. McBryan emphasizes the need for medical affairs to be seen as a strategic partner rather than a support function and advocates for closer collaboration between medical affairs, health economics, and outcomes research (HEOR) to demonstrate the value of drugs and address unmet needs. He also discusses the impact of digital transformation on medical affairs, including wearables, therapeutic digital solutions, social media, data analysis, and real-world evidence. McBryan envisions a future where medical affairs plays a more strategic role, engages with patients, and contributes to drug discovery and development. RESOURCES Danny MCBryan on LinkedIn Medical Affairs Professional Society The Future of Medical Affairs 2030…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
In this episode, Na-Ri and Ian interview Stacey Tinianov, an independent patient advocate and founder of Advocates for Collaborative Education. They discuss the importance of patient advocacy, the role of digital health, and the future of patient engagement. Stacey shares her personal journey into patient advocacy and highlights the gaps in knowledge and understanding she experienced as a breast cancer survivor. She emphasizes the need for human-centered design in healthcare, where patients are at the center of the design, development, and deployment of programs and technologies. Stacey also discusses the impact of digital platforms on patient engagement and the importance of building relationships and engaging with patients beyond a transactional level. Patient advocacy is a multifaceted field that encompasses various areas, including clinical trial advocacy, research advocacy, and policy advocacy. The future of patient advocacy lies in the expansion of voices and the focus on improving quality of life and survivorship. Advocates play a crucial role in shaping clinical trials, ensuring patient-reported outcomes are considered, and driving policy changes. The ultimate goal is to achieve true partnerships between advocacy and industry, as well as the decentralization of clinical trials. Patient advocates can effectively communicate by understanding their motivation and goals and tailoring their language to resonate with different stakeholders. The consequences of not getting patient advocacy right include a regression to the frustrating relationship patients had with pharmaceutical companies in the past. However, progress has been made, and patient advocacy has the potential to drive positive change in healthcare. Resources: Stacey Tinianov on LinkedIn Rabble Health Advocates for Collaborative Education International Cancer Advocacy Network Patient Advocate Foundation…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
Summary Dr. Andrée Bates, a pioneering force in the realm of artificial intelligence within the pharmaceutical industry, shares insights on the evolving role of AI in pharma, the future of healthcare innovation, and her advocacy for women in leadership. She discusses the early days of AI in pharma, the challenges faced, and the evolution of AI terminology. Dr. Bates also explores the application of AI in commercial insights and analytics, market access, drug discovery, and clinical trials. The conversation covers a wide range of topics related to the application of AI in the biopharma industry, including the use of synthetic data, digital twins, regulatory and medical affairs, market access, precision doctor targeting, and ethical implications. Dr. Andree Bates shares insights on the impact of AI on drug discovery, clinical trials, and patient care, as well as the potential for AI to revolutionize the industry. Resources Andree Bates on LinkedIn Eularis AI in biopharma research: A time to focus and scale AI in Biopharma: Use Cases and Considerations Artificial intelligence and its expanding role across the biopharma landscape…
 
R
RealPharma: Conversations with Pharma Pathfinders
RealPharma: Conversations with Pharma Pathfinders podcast artwork
 
Summary In this episode, Dr. Na-Ri Oh and Ian Wendt discuss Pharmacy Benefit Managers (PBMs) and their impact on drug pricing and patient access to medications. They are joined by Antonio Ciaccia, CEO of 46 Brooklyn Research and president of 3 Access Advisors, which provides insights into the role of PBMs in the drug supply chain. The conversation highlights the consolidation of power among the top three PBMs, their anti-competitive behaviors, and the need for increased scrutiny and regulatory measures. The discussion also explores the distorted incentive structures that favor high-cost drugs over lower-cost alternatives, leading to higher drug costs and limited access for patients. The conversation explores the impact of pharmacy benefit managers (PBMs) on drug costs and access to medications. The report states that PBMs control about 70% of all specialty drug revenue, leading to the closure of independent retail pharmacies in rural areas. The conversation emphasizes the need for transparency and accountability in the PBM industry. It also discusses the potential solutions, including market-based approaches and policy changes, to address the inefficiencies and anti-competitive behaviors of PBMs. Resources Antonio Ciaccia on LinkedIn Antonio Ciaccia on Twitter/X 3 Axis Advisors 46 Brooklyn Research FTC Interim Report on PBMs…
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

icon Daily Deals
icon Daily Deals
icon Daily Deals

快速参考指南

边探索边听这个节目
播放